Updates are available Correction dated 2022-06-18
Click to view Correction: https://doi.org/10.1186/s12931-022-02068-9
-
Authors
Yang, Ting
Cai, Baiqiang
Cao, Bin
Kang, Jian
Wen, Fuqiang
Chen, Yahong
Jian, Wenhua
Shang, Hongyan
Wang, Chen http://orcid.org/0000-0002-0529-2204
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03131362 at ClinicalTrials.govDocuments that mention this clinical trial
Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study
https://doi.org/10.1186/s12931-022-02021-w
-
Funding
Funding for this research was provided by:
AstraZeneca China
- License Information
-
More Information
Article History
Received: 19 March 2021
Accepted: 21 July 2021
First Online: 29 April 2022
Change Date: 18 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12931-022-02068-9
Declarations
:
: Written informed consent was obtained from all participants. The Ethics Committee of the China-Japan Friendship Hospital, the leading site, approved the study protocol and informed consent form (ICF) prior to study initiation (approval number 2016-97). All patients participating in this study voluntarily signed the ICF and received a copy before study initiation. The study was approved by ethics committees at individual study centres and performed in full conformance with the Declaration of Helsinki and Good Clinical Practice.
: Not applicable.
: TY, BCai, BCao, JK, FW, YC, WJ, and CW declare that they have no competing interests. HS is an employee of AstraZeneca China.
